162 related articles for article (PubMed ID: 21984908)
1. Improving a natural CaMKII inhibitor by random and rational design.
Coultrap SJ; Bayer KU
PLoS One; 2011; 6(10):e25245. PubMed ID: 21984908
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of the inhibition of calcium/calmodulin-dependent protein kinase II by pea protein-derived peptides.
Li H; Aluko RE
J Nutr Biochem; 2005 Nov; 16(11):656-62. PubMed ID: 16111873
[TBL] [Abstract][Full Text] [Related]
3. Studying CaMKII: Tools and standards.
Brown CN; Bayer KU
Cell Rep; 2024 Apr; 43(4):113982. PubMed ID: 38517893
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Target-Specific Screening Leads to Small-Molecule CaMKII Inhibitors.
Xu D; Li L; Zhou D; Liu D; Hudmon A; Meroueh SO
ChemMedChem; 2017 May; 12(9):660-677. PubMed ID: 28371191
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for cellular retinoic acid-binding protein 1 in modulating CaMKII activation.
Nhieu J; Miller MC; Lerdall TA; Mayo KH; Wei LN
Front Mol Biosci; 2023; 10():1268843. PubMed ID: 37822422
[No Abstract] [Full Text] [Related]
6. Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics.
Qvit N; Kornfeld OS; Mochly-Rosen D
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15672-15679. PubMed ID: 27860071
[TBL] [Abstract][Full Text] [Related]
7. Novel CaMKII-δ Inhibitor Hesperadin Exerts Dual Functions to Ameliorate Cardiac Ischemia/Reperfusion Injury and Inhibit Tumor Growth.
Zhang J; Liang R; Wang K; Zhang W; Zhang M; Jin L; Xie P; Zheng W; Shang H; Hu Q; Li J; Chen G; Wu F; Lan F; Wang L; Wang SQ; Li Y; Zhang Y; Liu J; Lv F; Hu X; Xiao RP; Lei X; Zhang Y
Circulation; 2022 Apr; 145(15):1154-1168. PubMed ID: 35317609
[TBL] [Abstract][Full Text] [Related]
8. Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial.
Boyle AJ; Schultz C; Selvanayagam JB; Moir S; Kovacs R; Dib N; Zlotnick D; Al-Omary M; Sugito S; Selvarajah A; Collins N; McLachlan G
JAMA Cardiol; 2021 Jul; 6(7):762-768. PubMed ID: 33851966
[TBL] [Abstract][Full Text] [Related]
9. The oral Ca/calmodulin-dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure.
Mustroph J; Drzymalski M; Baier M; Pabel S; Biedermann A; Memmel B; Durczok M; Neef S; Sag CM; Floerchinger B; Rupprecht L; Schmid C; Zausig Y; Bégis G; Briand V; Ozoux ML; Tamarelle D; Ballet V; Janiak P; Beauverger P; Maier LS; Wagner S
ESC Heart Fail; 2020 Oct; 7(5):2871-2883. PubMed ID: 32691522
[TBL] [Abstract][Full Text] [Related]
10. The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity.
Lebek S; Plößl A; Baier M; Mustroph J; Tarnowski D; Lücht CM; Schopka S; Flörchinger B; Schmid C; Zausig Y; Pagratis N; Marchand B; Koltun DO; Hung WK; Ahmadyar S; Belardinelli L; Maier LS; Wagner S
J Mol Cell Cardiol; 2018 May; 118():159-168. PubMed ID: 29614261
[TBL] [Abstract][Full Text] [Related]
11. Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor.
Neef S; Steffens A; Pellicena P; Mustroph J; Lebek S; Ort KR; Schulman H; Maier LS
J Mol Cell Cardiol; 2018 Feb; 115():73-81. PubMed ID: 29294328
[TBL] [Abstract][Full Text] [Related]
12. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis.
Zhang T; Zhang Y; Cui M; Jin L; Wang Y; Lv F; Liu Y; Zheng W; Shang H; Zhang J; Zhang M; Wu H; Guo J; Zhang X; Hu X; Cao CM; Xiao RP
Nat Med; 2016 Feb; 22(2):175-82. PubMed ID: 26726877
[TBL] [Abstract][Full Text] [Related]
13. Targeting CaMKII-δ9 Ameliorates Cardiac Ischemia/Reperfusion Injury by Inhibiting Myocardial Inflammation.
Yao Y; Li F; Zhang M; Jin L; Xie P; Liu D; Zhang J; Hu X; Lv F; Shang H; Zheng W; Sun X; Duanmu J; Wu F; Lan F; Xiao RP; Zhang Y
Circ Res; 2022 Mar; 130(6):887-903. PubMed ID: 35152717
[TBL] [Abstract][Full Text] [Related]
14. To Be or Not to Be a CaMKII Inhibitor?
Anderson ME
JAMA Cardiol; 2021 Jul; 6(7):769-770. PubMed ID: 33851950
[No Abstract] [Full Text] [Related]
15. CaMKII-δ9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair.
Zhang M; Gao H; Liu D; Zhong X; Shi X; Yu P; Jin L; Liu Y; Tang Y; Song Y; Liu J; Hu X; Li CY; Song L; Qin J; Wu F; Lan F; Zhang Y; Xiao RP
Nat Cell Biol; 2019 Sep; 21(9):1152-1163. PubMed ID: 31481791
[TBL] [Abstract][Full Text] [Related]
16. Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy.
Beauverger P; Ozoux ML; Bégis G; Glénat V; Briand V; Philippo MC; Daveu C; Tavares G; Roy S; Corbier A; Briand P; Dorchies O; Bauchet AL; Nicolai E; Duclos O; Tamarelle D; Pruniaux MP; Muslin AJ; Janiak P
Cardiovasc Res; 2020 Feb; 116(2):329-338. PubMed ID: 31038167
[TBL] [Abstract][Full Text] [Related]
17. The KN-93 Molecule Inhibits Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity by Binding to Ca
Wong MH; Samal AB; Lee M; Vlach J; Novikov N; Niedziela-Majka A; Feng JY; Koltun DO; Brendza KM; Kwon HJ; Schultz BE; Sakowicz R; Saad JS; Papalia GA
J Mol Biol; 2019 Mar; 431(7):1440-1459. PubMed ID: 30753871
[TBL] [Abstract][Full Text] [Related]
18. Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal.
Mesubi OO; Anderson ME
Cardiovasc Res; 2016 Apr; 109(4):542-57. PubMed ID: 26762270
[TBL] [Abstract][Full Text] [Related]
19. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone.
He BJ; Joiner ML; Singh MV; Luczak ED; Swaminathan PD; Koval OM; Kutschke W; Allamargot C; Yang J; Guan X; Zimmerman K; Grumbach IM; Weiss RM; Spitz DR; Sigmund CD; Blankesteijn WM; Heymans S; Mohler PJ; Anderson ME
Nat Med; 2011 Nov; 17(12):1610-8. PubMed ID: 22081025
[TBL] [Abstract][Full Text] [Related]
20. CaMKIIβ in Neuronal Development and Plasticity: An Emerging Candidate in Brain Diseases.
Nicole O; Pacary E
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
